| The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin S Xia, Q Lan, S Su, X Wang, W Xu, Z Liu, Y Zhu, Q Wang, L Lu, S Jiang Signal transduction and targeted therapy 5 (1), 92, 2020 | 328 | 2020 |
| Learning from the past: development of safe and effective COVID-19 vaccines S Su, L Du, S Jiang Nature Reviews Microbiology 19 (3), 211-219, 2021 | 188 | 2021 |
| Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein S Xia, Q Liu, Q Wang, Z Sun, S Su, L Du, T Ying, L Lu, S Jiang Virus research 194, 200-210, 2014 | 145 | 2014 |
| Antivirals with common targets against highly pathogenic viruses L Lu, S Su, H Yang, S Jiang Cell 184 (6), 1604-1620, 2021 | 92 | 2021 |
| From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development C Ma, S Su, J Wang, L Wei, L Du, S Jiang Microbes and Infection 22 (6-7), 245-253, 2020 | 54 | 2020 |
| Improved pharmacological and structural properties of HIV fusion inhibitor AP3 over enfuvirtide: highlighting advantages of artificial peptide strategy X Zhu, Y Zhu, S Ye, Q Wang, W Xu, S Su, Z Sun, F Yu, Q Liu, C Wang, ... Scientific reports 5 (1), 13028, 2015 | 43 | 2015 |
| Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy W Li, F Yu, Q Wang, Q Qi, S Su, L Xie, L Lu, S Jiang Aids 30 (6), 827-838, 2016 | 31 | 2016 |
| A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2 S Su, S Jiang Signal Transduction and Targeted Therapy 5 (1), 71, 2020 | 30 | 2020 |
| A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases J Zhou, W Xu, Z Liu, C Wang, S Xia, Q Lan, Y Cai, S Su, J Pu, L Xing, ... Acta Pharmaceutica Sinica B 12 (4), 1652-1661, 2022 | 28 | 2022 |
| Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern S Su, W Li, S Jiang Trends in immunology 43 (3), 170-172, 2022 | 28 | 2022 |
| A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity S Su, Q Wang, W Xu, F Yu, C Hua, Y Zhu, S Jiang, L Lu AIDS 31 (7), 885-894, 2017 | 27 | 2017 |
| Creating an artificial tail anchor as a novel strategy to enhance the potency of peptide-based HIV fusion inhibitors S Su, Y Zhu, S Ye, Q Qi, S Xia, Z Ma, F Yu, Q Wang, R Zhang, S Jiang, ... Journal of Virology 91 (1), 10.1128/jvi. 01445-16, 2017 | 27 | 2017 |
| An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene Z Sun, Y Zhu, Q Wang, L Ye, Y Dai, S Su, F Yu, T Ying, C Yang, S Jiang, ... Emerging microbes & infections 5 (1), 1-12, 2016 | 27 | 2016 |
| A peptide-based HIV-1 fusion inhibitor with two tail-anchors and palmitic acid exhibits substantially improved in vitro and ex vivo anti-HIV-1 activity and prolonged in vivo … S Su, G Rasquinha, L Du, Q Wang, W Xu, W Li, L Lu, S Jiang Molecules 24 (6), 1134, 2019 | 25 | 2019 |
| Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41 W Xu, J Pu, S Su, C Hua, X Su, Q Wang, S Jiang, L Lu AIDS 33 (10), 1545-1555, 2019 | 19 | 2019 |
| Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad‐spectrum, and safe COVID‐19 vaccines and therapeutics S Su, Q Wang, S Jiang Clinical and Translational Medicine 11 (1), 2021 | 14 | 2021 |
| Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile S Su, Z Ma, C Hua, W Li, L Lu, S Jiang Molecules 22 (11), 1996, 2017 | 14 | 2017 |
| Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations Y Zhu, S Su, L Qin, Q Wang, L Shi, Z Ma, J Tang, S Jiang, L Lu, S Ye, ... Scientific Reports 6 (1), 31983, 2016 | 14 | 2016 |
| Human challenge trials to assess the efficacy of currently approved COVID-19 vaccines against SARS-CoV-2 variants S Su, Y Shao, S Jiang Emerging Microbes & Infections 10 (1), 439-441, 2021 | 12 | 2021 |
| Double insult: flu bug enhances SARS-CoV-2 infectivity S Su, Z Liu, S Jiang Cell Research 31 (5), 491-492, 2021 | 11 | 2021 |
